Phase III trial to investigate combination of tocilizumab and remdesivir in severe COVID-19 pneumonia

The REMDACTA Phase III trial is expected to begin enrolling in June and involve 450 patients worldwide. Another Phase III trial comparing tocilizumab to placebo (COVACTA) has completed enrolment and results are expected later this year.


Biospace Inc.